Ulrich Keilholz is a medical oncologist and translational researcher. His experience is development and conduct of clinical trials in oncology ranging from phase I to phase III with integrated translational research projects and also preclinical drug development. He also serves as acting director of the CCCC, which includes responsibility for the cancer biobank, which is connected to the clinical cancer registry, and the CCCC clinical trial unit.
Staff in PREDICT:
Clinical trial design, data curation, clinical validation and exploitation of results
Most Relevant Publications:
Kruit WH, Suciu S, Dreno B, … , Lehmann FF, Brichard VG, Keilholz U (2013). Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 19:2413-2420
Eggermont AM, Suciu S, Testori A, … de Schaetzen G, Spatz A, Keilholz U (2012). Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30:3810-3818.
Tinhofer I, Klinghammer K, Weichert W, … , Gauler T, Budach V, Keilholz U (2011). Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) Receiving Cetuximab-Docetaxel Treatment. Clin Cancer Res 17:5197-5204.
Keilholz U, Letsch A, Busse A, … , Uharek L, Thiel E, Scheibenbogen C (2009). A Clinical and Immunological Phase II Trial of Wilms Tumor Gene Product 1 (WT1) Peptide Vaccination in Patients with AML and MDS. Blood 113:6541-6548.
Tjulandin S, Moiseyenko V, Semiglazov V, … M, Saunders A, Stuart M, Keilholz U (2013). Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Invest New Drugs.